[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352035-105":59,"doc-detail-352035-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synthetic-lethality-between-pbrm1-deficiency-and-parp-inhibitors-exploiting-g2m-checkpoint-arrest-in-colorectal-cancer","Synthetic lethality between PBRM1 deficiency and PARP inhibitors - exploiting G2/M checkpoint arrest in colorectal cancer","","Research focusing on PBRM1, a frequently lost BAF180 subunit of the PBAF chromatin-remodeling complex, addresses the lack of tailored treatments for PBRM1-defective cancers. A synthetic-lethality approach tests whether clinically used PARP inhibitors selectively suppress PBRM1-deficient colorectal cancer cells. The work links PARP inhibition to cell-cycle and stress-response mechanisms, and compares it with broader chromatin-remodeler targeting to define precision dependencies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synthetic-lethality-between-pbrm1-deficiency-and-parp-inhibitors-exploiting-g2m-checkpoint-arrest-in-colorectal-cancer/352035/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synthetic-lethality-between-pbrm1-deficiency-and-parp-inhibitors-exploiting-g2m-checkpoint-arrest-in-colorectal-cancer/352035.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is PBRM1 and why is it relevant to cancer therapy?","Question",{"text":112,"@type":113},"PBRM1 encodes the BAF180 subunit of the PBAF chromatin-remodeling complex. Its loss or decreased expression is common across malignancies, yet targeted therapies for PBRM1-defective cancers are limited.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study test PARP inhibitors in PBRM1-deficient colorectal cancer cells?",{"text":117,"@type":113},"Isogenic PBRM1 knockout HCT116 cells were generated using CRISPR/Cas9 lentiviral editing. The researchers screened PARP inhibitors and compared effects to broader chromatin-remodeler targeting using viability assays and colony-formation validation.",{"name":119,"@type":110,"acceptedAnswer":120},"What cellular mechanism links PBRM1 loss to PARP inhibitor sensitivity?",{"text":121,"@type":113},"PBRM1 loss is reported to increase hypersensitivity to PARP inhibitors. The inhibitors intensify DNA-damage signaling, promote G2/M checkpoint arrest, trigger apoptosis, and induce stress-response genes such as CSRNP3.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352035,1790912205,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Islam etal. Molecular Medicine (2026) 32:125 Molecular Medicine  \n[https://doi.org/10.1186/s10020-026-01525-1](https://doi.org/10.1186/s10020-026-01525-1)  \nRESEARCH Open Access  \nSynthetic lethality between PBRM1 deficiency  and PARP inhibitors: exploiting G2/M checkpoint arrest in colorectal cancer  \nMohdTarequl Islam1,2, Haiwei Quan3, Shuangquan Chen1, Zhiguang Xu1,3, Mingzhou Guo4 and Zhibin Wang1,3*  \nAbstract  \nBackground Polybromo 1 (PBRM1), encoding the BAF180 subunit of the polybromo-associated BAF (PBAF) chromatin-remodeling complex, is commonly lost or mutated across malignancies. Despite its prevalence, tailored therapeutics for PBRM1-defective cancers remain limited. PBRM1 loss is associated with elevated replication stress and DNA damage responses, implying dependence on compensatory repair pathways. Given the lack of genotypematched drugs, exploiting DNA-repair dependencies may provide a precision option for PBRM1-deficient disease. We pursued a synthetic-lethality strategy in colorectal cancer to test whether clinically used PARP inhibitors selectively suppress PBRM1-deficient cells and to define the linked cell-cycle and stress-response mechanisms. We also compared PARP inhibition with broader chromatin-remodeler targeting.  \nMethods Isogenic PBRM1−/− HCT116 colorectal carcinoma cells were generated by CRISPR/Cas9 lentiviral editing using sgRNAs cloned into lenti-CRISPR-V2 . Knockout was confirmed by Western blotting, Sanger sequencing, and RT-qPCR. A focused compound screen compared four agents PARP inhibitors olaparib and rucaparib, the multi-target chromatin remodeler inhibitor AU-24,118, and the SMARCA2/4-targeting degrader AU-1530 using dose-response CCK-8 viability assays and selectivity indices. We then validated our results by 12-day colony-formation assays. Mechanistic analyses measured drug-induced G2/M accumulation by propidium iodide staining and flow cytometry and quantified apoptosis by Annexin V/PI dual staining, with significance assessed by t-test or two-way ANOVA. Conclusions PBRM1 loss confers selective hypersensitivity to PARP inhibitors, which intensify DNA-damage signaling, promote G2/M checkpoint arrest, trigger apoptosis, and induce stress-response genes such as CSRNP3 . Although this effect appears context-dependent and was not observed uniformly across all PBRM1−/− models tested. These results support further evaluation of PBRM1 as a potential predictive biomarker in defined molecular contexts rather than asa universal marker of PARP inhibitor sensitivity.  \nKeywords SWI/SNF chromatin remodeling complexes, PBRM1 deficiency, PARP inhibitors, Synthetic lethality, HCT116  \n*Correspondence:  \nZhibin Wang  \n[wangzhibin@suat-sz.edu.cn](wangzhibin@suat-sz.edu.cn)  \n1Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China  \n2University of Chinese Academy of Sciences, Beijing, China 3Department of Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology,  \nShenzhen 518107, China  \n4Department of Gastroenterology and Hepatology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not","cbCaib5BNoMZ949J","https://ap.wps.com/l/cbCaib5BNoMZ949J","pdf",3463452,13,"English","# Abstract\n## Background\n## Methods\n## Conclusions\n# Background\n## PBRM1 biology and prevalence in cancers\n## Rationale for synthetic-lethality strategy","[{\"question\":\"What is PBRM1 and why is it relevant to cancer therapy?\",\"answer\":\"PBRM1 encodes the BAF180 subunit of the PBAF chromatin-remodeling complex. Its loss or decreased expression is common across malignancies, yet targeted therapies for PBRM1-defective cancers are limited.\"},{\"question\":\"How did the study test PARP inhibitors in PBRM1-deficient colorectal cancer cells?\",\"answer\":\"Isogenic PBRM1 knockout HCT116 cells were generated using CRISPR/Cas9 lentiviral editing. The researchers screened PARP inhibitors and compared effects to broader chromatin-remodeler targeting using viability assays and colony-formation validation.\"},{\"question\":\"What cellular mechanism links PBRM1 loss to PARP inhibitor sensitivity?\",\"answer\":\"PBRM1 loss is reported to increase hypersensitivity to PARP inhibitors. The inhibitors intensify DNA-damage signaling, promote G2/M checkpoint arrest, trigger apoptosis, and induce stress-response genes such as CSRNP3.\"}]","Synthetic lethality between PBRM1 deficiency and PARP inhibitors - exploiting G2/M checkpoint arrest in colorectal cancer | PDF",1790097301,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10a7d20ebe0c9202a53e0cd261530378.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b6f7cbf86484b52068517284ec3dc54.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e788618bdf77e511971644c385fb7bc.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5dedbd595c13285ca538f7e87c3ec41.webp",980,1306]